ArticleScientific reports2026
Association of the novel remnant cholesterol inflammatory index with acute coronary syndrome risk in hospitalized patients with diabetes: a two-center study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Remnant cholesterol and low-grade inflammation are key contributors to acute coronary syndrome (ACS) in patients with diabetes mellitus. The novel remnant cholesterol inflammatory index (NRCII), combining remnant cholesterol (RC) and the neutrophil-to-lymphocyte ratio (NLR), may enhance risk stratification, but its clinical relevance in diabetic inpatients remains unclear. This multicenter retrospective study included 3664 diabetic inpatients hospitalized between August 2019 and June 2025. Logistic regression, restricted cubic spline (RCS), subgroup, and sensitivity analyses were conducted to assess the association between NRCII and ACS. Incremental predictive value was evaluated using C-statistic, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and likelihood-ratio (LR) tests. ACS occurred in 1056 participants (28.8%). Each 1-unit increase in NRCII was associated with a 21% higher risk of ACS in the fully adjusted model (OR = 1.21, 95% CI 1.13-1.29, P < 0.001). Quartile analyses showed a clear dose-response (P for trend < 0.001), with the highest quartile showing nearly three-fold greater risk (OR = 2.78, 95% CI 1.86-4.04) compared to the lowest. RCS confirmed a significant nonlinear positive association. Results remained robust after excluding patients on lipid-lowering therapy. Subgroup analyses revealed interactions with age and alcohol use. NRCII addition to the clinical model provided the greatest performance gain (C-statistic 0.751; NRI 0.271; IDI 0.020; LR 30.63; all P < 0.001) over RC or NLR alone. Higher NRCII is independently and strongly associated with ACS risk among hospitalized patients with diabetes, offering superior predictive value compared to RC or NLR alone. NRCII may serve as a simple, effective tool for ACS risk stratification in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.